Sixth Street Partners has entered a $500 million strategic financing agreement with Arrowhead Pharmaceuticals to fund growth opportunities across Arrowhead’s pipeline of RNAi therapeutics. San Francisco-based Sixth Street Partners was advised by Proskauer Rose and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo. Arrowhead Pharmaceuticals, which is based in Pasadena, California, was represented by a Gibson, Dunn & Crutcher corporate team led by partners Ryan Murr and Jin Hee Kim.
Biotech & Pharmaceuticals
August 13, 2024, 12:39 PM